Max Gelman Associate Editor Christmas has come early for Urovant Sciences as the former Vivek Ramaswamy outfit scored an FDA approval for its lead program. James Robinson The biotech’s overactive bladder candidate vibegron will be the newest drug to hit the market, the agency said Wednesday, giving Urovant its first approved product. Vibegron, a beta-3...